MedTrace Logo

Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers

NCT02222454 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-02-23

No results posted yet for this study

Summary

The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with stage II or III pressure ulcers.

Conditions

  • Pressure Ulcers Stage II
  • Pressure Ulcers Stage III

Interventions

DEVICE

KLOX BioPhotonic System

KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.

Sponsors & Collaborators

  • KLOX Technologies Inc.

    lead INDUSTRY

Principal Investigators

  • David Keast, Dr · Lawton Research Institute, London, Ontario, Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02222454 on ClinicalTrials.gov